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Abstract 6 
The mechanisms by which noxious stimuli produce the sensation of pain in animals are 7 
complex. Noxious stimuli are transduced at the periphery and transmitted to the CNS, where 8 
this information is subject to considerable modulation. Finally, the information is projected to 9 
the brain where it is perceived as pain. Additionally, plasticity can develop in the pain 10 
pathway and hyperalgesia and allodynia may develop through sensitisation both peripherally 11 
and centrally. A large number of different ion channels, receptors, and cell types are involved 12 
in pain perception, and it is hoped that through a better understanding of these, new and 13 
refined treatments for pain will result. 14 
 15 
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Introduction 17 
Pain is the subjective experience of harm in a part of one's body, and is currently more 18 
strictly defined as "an unpleasant sensory and emotional experience associated with actual or 19 
potential tissue damage, or described in terms of such damage" (Williams and Craig, 2016). 20 
By this definition it is an experience, which therefore requires activity of structures in the 21 
brain to be perceived. This is in contrast to nociception which is defined as the encoding and 22 
processing of noxious stimuli in the nervous system. Pain has a fundamentally important 23 
protective role, alerting us to threats and providing an impetus for the preservation of the 24 
integrity of the body. However, in the context of veterinary treatment of illness or injury, 25 
acute pain may become an unwanted consequence that compromises the welfare of animals 26 
in our care. The implications of chronic pain, which is generally defined as pain that extends 27 
beyond the normal duration of healing, can be even more detrimental to wellbeing and is 28 
covered in another article within this issue. 29 
A wide variety of thermal, chemical, mechanical and inflammatory stimuli can trigger pain 30 
and the experience of clinical pain is likely a complex amalgam of these stimuli perceived 31 
after significant modulation in the central nervous system. Pain may also result from a lesion 32 
or disease of the nervous system itself. However, the complex mechanisms of this so-called 33 
neuropathic pain, which have received significant attention from pain researchers, are not 34 
covered in detail in this review.  35 
The nociceptive pathway that carries signals from the periphery to the brain where pain is 36 
perceived can be broken into components: Transduction of noxious stimuli at the periphery, 37 
transmission of those stimuli to the central nervous system (CNS), central integration and 38 
modulation of the signals at the CNS level, and finally projection to the brain followed by 39 
perception. This article aims to detail the important cellular and molecular mechanisms of 40 
each of these stages.  41 
Transducing the stimulus at the periphery; the role of the nociceptor. 42 
Nociceptors are primary afferent neurons which project from tissues including skin, muscle, 43 
joints and viscera to the spinal cord or its trigeminal equivalent in the brainstem. Unlike other 44 
classes of primary afferents, e.g. those that convey touch, nociceptors preferentially  45 
transduce stimuli with intensities in the noxious range allowing them to respond to injurious 46 
stimuli (Basbaum et al., 2009).  Anatomically, the cell bodies of nociceptors are located in 47 
the dorsal root ganglia (DRG) adjacent to the spinal cord or in the trigeminal ganglia in the 48 
case of sensory information arising from the face. Their axons arise from these cell bodies 49 
and have both a peripheral branch that innervates the tissues where stimuli are transduced, 50 
and central branch innervating the spinal cord. While other classes of sensory primary 51 
afferents may have complex peripheral apparatus for the detection of stimuli, e.g. Meissner’s 52 
corpuscles for low threshold touch, nociceptors are present at the periphery as simple 53 
branched free nerve endings (Lumpkin and Caterina, 2007). Despite this apparently simple 54 
anatomical arrangement, nociceptors have a complex array of cellular and molecular 55 
machinery that enables stimulus transduction, as detailed below. 56 
Classifying Nociceptors 57 
Primary afferent neurons are classically characterised by their diameter and degree of 58 
myelination which both determine their conduction velocity (see Table 1). Most large 59 
myelinated afferents (termed Aβ fibres) are low frequency mechanoreceptors which respond 60 
to touch or hair movement (Abraira and Ginty, 2013). Two major classes of nociceptor exist. 61 
The first are medium diameter, myelinated afferents (Aδ) and these are responsible for the 62 
transmission of well-localised ‘fast’ or ‘first’ pain (Ringkamp et al., 2013). The second are 63 
unmyelinated, small C-fibre nociceptors which convey poorly localised ‘slow’ pain. The Aδ 64 
nociceptors can be further subdivided into two functional groups (Treede et al., 1998). Type I 65 
Aδ nociceptors respond to mechanical and chemical stimuli but have high heat thresholds but 66 
will sensitise in the context of tissue injury. These fibres are probably responsible for ‘first’ 67 
pain from mechanical stimuli such as a pin prick. Type II fibres have a much lower heat 68 
threshold and a high mechanical threshold and are involved in ‘fast’ pain responses to heat. 69 
Mammalian C-fibre nociceptors can be further classified, not by their functional or 70 
conduction properties but on a molecular basis based on receptors and neurochemicals that 71 
they express. A wide range of markers has been studied with the aim of defining neuronal 72 
subpopulations and correlating these with the response properties of the nociceptors. It is 73 
common practice to divide the nociceptive C-fibres into two groups; the peptidergic fibres 74 
marked by the expression of calcitonin gene-related peptide (CGRP) and substance P, and the 75 
non-peptidergic group identified by their binding of isolectin B4 (IB4) (Snider and 76 
McMahon, 1998). A plethora of other single markers, such as the transient receptor potential 77 
channels (TRP channels) and the Mrg family of G-protein linked receptors, have been 78 
suggested to define functional populations (Zhang et al., 2013) but recent unbiased molecular 79 
strategies aiming to define classes within all sensory primary afferents indicate the situation 80 
is clearly more complex (Li et al., 2016; Usoskin et al., 2014). These studies have sought to 81 
define primary afferent heterogeneity using modern molecular techniques to analyse mRNA 82 
transcripts in the cell bodies of DRG neurons. Individual cells can then be classified, not by a 83 
single marker, but by the constellation of genes that they express. The result is that primary 84 
afferents are grouped on a molecular basis into ten or eleven subgroups and in one study the 85 
functional significance of these groups has been interrogated (Li et al., 2016). 86 
It is of interest that not all sensory C-fibres are nociceptive. Small subgroups of C fibres 87 
appear to be specifically responsible for itch transduction and are termed pruritoceptors (Han 88 
et al., 2013; Mishra and Hoon, 2013). Additionally, two small classes of C-fibres are low 89 
threshold afferents (termed C low threshold mechanoreceptors, (C-LTMR)) that are involved 90 
in the transduction of pleasant or gentle touch sensations (Seal et al., 2009; Vrontou et al., 91 
2013). 92 
Much of the knowledge about nociceptors is derived from those that innervate the skin, so 93 
called cutaneous nociceptors, rather than those that innervate the viscera and convey the 94 
impulses that can lead to the sensation of visceral pain. As such, much of what is presented in 95 
this section is relevant only to cutaneous nociceptors. In some respects, visceral sensory 96 
neurons with the capacity to convey nociceptive information are similar to cutaneous 97 
nociceptors; their cell bodies are present in the DRG (or nodose ganglia in the case of vagal 98 
visceral afferents), and they generally possess thinly myelinated or unmyelinated axons and 99 
small to medium sized cell bodies (i.e. Aδ & C fibres).  Some visceral afferents, however, 100 
traverse pre- and paravertebral ganglia en route to the spinal cord (Gebhart and Bielefeldt, 101 
2011). Importantly, the viscera are sparsely innervated compared to the non-visceral tissues, 102 
and visceral nociceptors have markedly different response properties. Specifically, visceral 103 
nociception and hence pain does not arise from cutting or burning of organs, rather it arises 104 
from distension, traction, ischaemia and through release of chemical mediators of 105 
inflammation. While our knowledge of the biochemical differences underlying these 106 
functional differences is incomplete, it is safe to say that the make-up of receptors and ion 107 
channels present on visceral nociceptors is unique, and several notable differences have been 108 
reported (Robinson and Gebhart, 2008). 109 
Mechanisms of stimulus transduction 110 
Acute noxious stimuli may be thermal, mechanical or chemical and specific ion channels and 111 
G-protein linked receptors are involved in conversion of the stimulus into electrical signals in 112 
the primary afferents. These channels generate an electrical current through either opening, 113 
hence allowing the influx of Na+ or Ca2+, or closing if the channel is responsible for a 114 
hyperpolarising current (e.g. a K+ channel) (Gold, 2013). Many chemical stimuli act via G-115 
protein linked receptors and in these cases intracellular signalling pathways indirectly modify 116 
ion channel activity. 117 
The specific channels and receptors that transduce stimuli have been studied extensively with 118 
the transient receptor potential channels (TRP channels) being of importance. In the case of 119 
heat sensation the TRP Vanilloid 1 (TRPV1) channel would appear to play a prominent role 120 
(Cavanaugh et al., 2009). This is of particular interest as TRPV1 is the receptor for capsaicin, 121 
the active ingredient in chilli peppers, and there has been significant attention paid to 122 
developing drugs acting here (Brown, 2016). TRPV1 is one of some 30 or so members of the 123 
transient receptor potential family with other channels also important for stimulus 124 
transduction. TRP Melastatin 8 (TRPM8), the receptor for menthol, is proposed to have 125 
major roles in the transduction of cold stimuli (Bautista et al., 2007). Other thermotransducers 126 
also contribute to temperature sensation and these include two-pore potassium channels 127 
(K2P) (Noël et al., 2009) and voltage gated sodium channels (Zimmermann et al., 2007). A 128 
number of candidate proteins have also emerged as important contributors to noxious 129 
mechanosensation. These include the acid-sensitive ion channels (ASICs) (Omerbašić et al., 130 
2015), Piezo channels (Coste et al., 2010) , TRP Ankyrin 1 (TRPA1) (Corey et al., 2004), and 131 
K2P channels , although the molecular basis for mechanotransduction requires further 132 
clarification (Basbaum et al., 2009). 133 
The ability to detect chemical signals is an important requirement for an organism for 134 
avoiding both environmental noxious chemicals and also to detect endogenous irritants that 135 
may be produced as a result of injury and inflammation. The TRP channels are particularly 136 
important here acting as the receptors for capsaicin (TRPV1), mustards and garlic (TRPA1), 137 
and a wide array of other chemical irritants (e.g. TRPA1 transduces the aversive smell of 138 
isoflurane). A number of ion channels (e.g. ASICS) and a wide variety of G-protein linked 139 
receptors are present on peripheral nociceptor terminals (Yaksh et al., 2015) which can sense 140 
the substances produced by the process of inflammation and sensitise the nociceptor giving 141 
rise to lower thresholds. These mechanisms are discussed in more details below. However, it 142 
is also worth stating that a number of mechanisms exist whereby nociceptor activity can be 143 
modulated peripherally (Pan et al., 2008). Antinociceptive G-protein receptors involved 144 
include opioid, cannabinoid, somatostatin, muscarinic acetylcholine, GABAB, and α2-145 
adrenergic receptors and most appear to primarily act via modulation of Ca2+ channels thus 146 
reducing Ca2+ entry. This appears to be highly relevant following clinical administration of 147 
exogenous opioid agonists at peripheral sites where they can produce significant analgesic 148 
and anti-inflammatory effects (Iwaszkiewicz et al., 2013; van Loon et al., 2010). 149 
Transducing the stimulus in the context of inflammation 150 
Disease and injury often results in pain that is not explained simply by the transduction of 151 
noxious stimuli as explained above. This so called inflammatory pain is the result of 152 
endogenously generated factors which can activate nociceptor terminals (Dawes et al., 2013). 153 
In addition, these substances can also sensitise nociceptors, which is to lower their response 154 
threshold and increase their response to a given stimulus.  This process is termed peripheral 155 
sensitisation and the result for the animal are the phenomena of hyperalgesia, where painful 156 
stimuli are perceived as more painful, and allodynia, where non-noxious stimuli are perceived 157 
as painful. 158 
Inflammatory mediators may be released by a multitude of non-neuronal cells including 159 
fibroblasts, keratinocytes, platelets and immune cells, as well as from the peripheral terminals 160 
of activated nociceptors themselves; so called neurogenic inflammation (Chiu et al., 2012). 161 
These mediators include prostaglandins, leukotrienes, bradykinin, serotonin, histamine, 162 
CGRP, substance P, purines such as ATP, protons, free radicals, lipids, cytokines, 163 
chemokines, and neurotrophins such as nerve growth factor (NGF) (Yaksh et al., 2015). 164 
Sensitisation may then occur by one of 3 mechanisms; i) direct activation of cation channels 165 
causing nociceptor activation, ii) activation of intracellular regulatory pathways via G-166 
proteins to indirectly alter (e.g. phosphorylate) membrane proteins, or iii) alterations to the 167 
transcriptional phenotype of the cell (Dawes et al., 2013).  In the case of cytokines and 168 
chemokines, while some evidence exists to suggest a direct action on nociceptors, their 169 
proalgesic action most likely arises from the strengthening of the inflammatory response and 170 
consequent release of other mediators.  171 
 A number of factors present in the ‘inflammatory soup’ have received particular attention in 172 
terms of the development of therapeutics to target inflammatory pain and peripheral 173 
sensitisation. Prostaglandins, leukotrienes and thromboxanes, collectively termed 174 
eicosanoids, are thought to sensitise nociceptors rather than activate them directly (Pethő and 175 
Reeh, 2012) but the inhibition of prostaglandin synthesis by cyclooxygenase inhibitors is a 176 
common and efficacious approach to pain treatment (KuKanich et al., 2012).  Inhibition of 177 
other lipid inflammatory mediators, such as the soluble epoxide hydrolase pathway shows 178 
promise (Guedes et al., 2017). Antagonism of the prostaglandin E2 receptor has also proved 179 
to be an efficacious treatment for osteoarthritis pain in dogs (Rausch-Derra et al., 2016), 180 
which may have a reduced risk of adverse effects compared to conventional cyclooxygenase 181 
inhibition. Nerve growth factor is released during inflammation and acts via the tyrosine 182 
kinase (TrkA) receptor expressed on nociceptors to produce hyperalgesia. A potential 183 
therapeutic approach to pain that is being investigated is the use of monoclonal antibodies to 184 
NGF to reduce its action (Lascelles et al., 2015). 185 
Transmission of the Stimulus 186 
Once the noxious stimulus has been transduced at the periphery it must be transmitted as an 187 
action potential to the central nervous system. Voltage-gated sodium and potassium channels 188 
are involved in the generation of this action potential. Different classes of sodium channels, 189 
such as Nav 1.1, Nav 1.6, Nav 1.7, Nav 1.8 and Nav 1.9, are expressed in sensory neurons, 190 
with the later three being predominantly expressed in nociceptors.  Recently, mutations 191 
within the Nav 1.7 channel have been shown to underlie dramatic insensitivities to pain in 192 
human subjects (Cox et al., 2006) while gain of function mutations here have been shown to 193 
cause painful disorders.  As sodium channel subtypes seem to be differentially expressed in 194 
nociceptive and non-nociceptive primary afferents, there has been interest in these targets for 195 
the development of novel analgesics (Emery et al., 2016). Voltage-gated calcium channels 196 
are involved in neurotransmitter release at central and peripheral terminals. Calcium channels 197 
are composed of α1 pore forming subunits and α2 modulatory subunits. The α2δ subunit is 198 
highly expressed in C nociceptors particularly after nerve injury and is an analgesic target of 199 
gabapentin (Li et al., 2006).  200 
Integration in the Dorsal Horn of the Spinal Cord 201 
The dorsal horn of the spinal cord is the site of the first synapse of the primary afferent 202 
neuron and is a site of tremendous modulation and integration of sensory information before 203 
it is projected to the brain. Given the remarkable heterogeneity in the neurobiology of 204 
nociceptive primary afferents, we are at an early stage in terms of our understanding of how 205 
these inputs both transmit specific stimuli and how this is deciphered by the CNS thereby 206 
resulting in a pain percept. The dorsal horn undeniably plays a major role in this processing  207 
and whist the theoretical frameworks for pain processing are beyond the scope of this review, 208 
those interested readers are referred to an excellent review by Moayedi and Davis (2013). 209 
The grey matter of the spinal cord is divided into laminae based on cytoarchitectonic criteria 210 
(fig 1) (Rexed, 1952). The superficial dorsal horn receives the majority of nociceptive 211 
afferent input and is composed of laminae I and II. In this area the dorsal horn contains 4 212 
basic neural components: the central terminals of primary afferent neurons, excitatory and 213 
inhibitory interneurons, projection neurons and descending modulatory axons (Todd, 2010).  214 
Primary afferents terminate in the dorsal horn in a well-ordered fashion determined by fibre 215 
type within a somatotopic arrangement. The input to the dorsal horn is also stratified by 216 
somatosensory modality. Aδ nociceptors end mainly in lamina I, peptidergic primary 217 
afferents arborize mainly in laminae I and II outer whereas most non-peptidergic C fibres 218 
form a band occupying the central part of lamina II (Fig 1). Non-nociceptive afferents such as 219 
Aβ tactile fibres end mainly in the deeper laminae III-V (Abraira et al., 2017). Within this 220 
arrangement synapses with second-order neurons may have simple single synaptic 221 
arrangements or may form complex synaptic glomeruli which give rise to numerous synapses 222 
and receive axo-axonic inhibitory inputs from local interneurons (Ribeiro-da-Silva and 223 
Coimbra, 1982). Primary afferents all use glutamate as their principle neurotransmitter and 224 
hence all synapses with second order neurons are excitatory. These second order neurons 225 
receiving synapses may be interneurons which form complex circuits within the dorsal horn, 226 
or projection neurons. 227 
Visceral nociceptive primary afferents arborise in a unique way in the dorsal horn and this 228 
pattern of innervation, alongside the fact that the viscera are comparatively sparsely 229 
innervated, underlies the often diffuse and poorly localised nature of visceral pain. These 230 
afferents project extensively to both superficial and deep laminae (I, II, V & X) but notably 231 
spread out over several spinal segments and may decussate on the opposite side of the cord 232 
(Gebhart and Bielefeldt, 2011). Viscerosomatic convergence is common, such that almost all 233 
second order spinal neurons receiving visceral input also receive somatic input from skin or 234 
muscle. This provides an explanation for the phenomenon of referred pain, where visceral 235 
nociception is not perceived at the site of origin, rather at an adjacent or distant somatic site 236 
(Cervero, 1994). A good example of this is pain felt in the shoulder which results from gas 237 
accumulation in the abdomen and consequent diaphragmatic irritation following laparoscopy. 238 
Projection Neurons; the Output from the Dorsal Horn 239 
For a noxious stimulus to be perceived as painful, it must first be projected to higher centres 240 
in the brain. Nociceptive specific projection neurons are concentrated in lamina I and 241 
scattered through laminae III-VI. Projection neurons in deeper laminae (V) may not be 242 
specific to noxious stimuli and are termed wide dynamic range neurons (WDR) as they 243 
respond to a broad range of input and encode stimulus intensity (Sikandar et al., 2013). 244 
Despite their importance, projection neurons only comprise around 5% of the cells in the 245 
superficial dorsal horn (Spike et al., 2003).   246 
The axons of these projection cells cross the midline, travel in ascending spinal white matter 247 
tracts and innervate various brainstem and thalamic nuclei. The white matter tracts involved 248 
in the projection of nociceptive information vary depending on species; the spinothalamic 249 
tract would appear to be most important in humans and primates, the spinocervicothalamic 250 
tract predominant in carnivores, and the spinoparabrachial tract most important in rodents 251 
(Dostrovsky and Craig, 2013). The brainstem and thalamic nuclei receiving projections 252 
include the medulla (caudal ventrolateral medulla (CVLM) & the rostral ventromedial 253 
medulla (RVM)), the parabrachial area (Pb), the periaqueductal grey (PAG), the nucleus of 254 
the solitary tract (NTS) and the thalamus (Figure 2). Each of these areas is believed to code 255 
for specific dimensions of the pain experience (West et al., 2015). The parabrachial area is 256 
thought to be particularly important in terms of the affective component of pain as its output 257 
provides for a rapid connection to the amygdyla and hypothalamus.  The thalamus has been 258 
associated with the sensory-discriminatory aspects of pain due to its connections to the 259 
somatosensory cortex. Both the PAG and CVLM are thought to be upstream of other 260 
brainstem areas that control powerful descending inputs to the spinal cord (see below). 261 
The majority (80%) of lamina I projection neurons express the neurokinin 1 receptor (NK1r) 262 
upon which substance P acts. This receptor has attracted considerable interest as selective 263 
ablation of the cells expressing NK1r reduces hyperalgesia in inflammatory, cancer and 264 
neuropathic pain models (Mantyh et al., 1997) including in studies conducted in clinical 265 
canine patients (Brown and Agnello, 2013).  266 
Synaptic Mechanisms and Plasticity 267 
As mentioned above, all synapses from primary afferents onto second order neurons are 268 
excitatory and use glutamate as a neurotransmitter. Although glutamate is the primary 269 
neurotransmitter, it can be co-localised with the neuropeptides substance P and CGRP, which 270 
also play a role in nociceptive signalling (De Biasi and Rustioni, 1988). Glutamate acts on 271 
three ionotropic receptors; the kainate receptor, the alpha-amino3-hydroxy-5-methy-4-272 
isoxazoleproprionic acid (AMPA) receptor, and the N-methyl-D-aspartate (NMDA) receptor. 273 
It also acts via the metabotropic glutamate receptor (mGlu). 274 
Synapses within the dorsal horn display activity-dependent plasticity in response to 275 
prolonged or high intensity noxious input (Sandkühler, 2009). A result of this inherent 276 
plasticity is facilitation of the signal such that the information relayed to higher centres is not 277 
coupled to the intensity or duration of the peripheral stimulus (Latremoliere and Woolf, 278 
2009). This phenomenon is commonly termed central sensitisation and results in hyperalgesia 279 
and allodynia. Central sensitisation can be readily and rapidly elicited in human volunteers, 280 
thus is important in the physiology of acute pain as well as being commonly present in many 281 
chronic pain syndromes in humans (Woolf, 2011). The desire to avoid the induction of 282 
central sensitisation also underlies the desire of many anaesthetists to practice preemptive 283 
analgesia for surgery. Here, central sensitisation is reduced by the use of analgesics to block 284 
the intraoperative nociceptive barrage, thus reducing the magnitude of postoperative acute 285 
pain. While this concept has proved controversial and difficult to prove in the human pain 286 
literature (Katz et al., 2011), evidence in veterinary species is encouraging (Lascelles et al., 287 
1997) and the concept has been validated experimentally (LaMotte et al., 1992). 288 
Multiple mechanisms underlie central sensitisation but it is well established that the NMDA 289 
receptor plays an integral role as its antagonism inhibits activity-dependent plasticity 290 
(Bergadano et al., 2009; Dickenson and Sullivan, 1987). The NMDA receptor is usually 291 
blocked by a Mg2+ ion at resting membrane potential. When the post-synaptic neuron 292 
undergoes sustained depolarisation due to the actions of glutamate and also SP and CGRP, 293 
this blockade is lifted and glutamate can activate the receptor. This results in a greater influx 294 
of Na+ and Ca2+ and thus amplification of the signal. Subsequent maintenance of central 295 
sensitisation occurs due to increases in activity of a number of second messenger systems as a 296 
result of an increase in cytosolic Ca2+. Increased activity of intracellular kinases serves to 297 
phosphorylate receptors, recruit new receptors and alter gene expression resulting in altered 298 
synaptic responses and continuation of sensitisation (Sandkühler and Gruber-Schoffnegger, 299 
2012).  300 
Conversely, a number of endogenous mechanisms may reduce synaptic transmission; the 301 
three principle opioid receptors (mu, delta and kappa) are present in high concentrations both 302 
pre and post-synaptically in the dorsal horn. Pre-synaptically, opioid receptor activation 303 
reduces neurotransmitter release via reducing calcium influx and this is the major mechanism 304 
of their analgesic action here (Kohno et al., 1999). It should be noted that opioids also exert a 305 
significant effect at supra-spinal levels, particularly at the level of the rostral ventromedial 306 
medulla (RVM). Additional endogenous modulation of noxious inputs to the dorsal horn may 307 
occur via descending mechanisms, or inhibitory circuits as discussed below. 308 
Spinal Cord Circuitry 309 
The concept of the dorsal horn as a site of modulatory circuits for noxious signals dates back 310 
to Wall and Melzack’s gate control theory (GCT) of pain (Melzack and Wall, 1965). GCT 311 
proposed that the extent to which a stimulus produced pain was not just a function of the 312 
magnitude of the signal in nociceptive specific primary afferents, rather this activity could be 313 
modulated at the level of the spinal cord by non-nociceptive afferents.  At the centre of the 314 
gate control circuit lies an inhibitory interneuron which can be activated by the large fibres 315 
resulting in feed-forward inhibition of the action system. Nociceptive specific primary 316 
afferents not only activate the action system but also reduce the activity of the ‘gating’ 317 
inhibitory interneuron. It has been demonstrated that the selective inactivation of large 318 
populations of inhibitory interneurons in the dorsal horn results in spontaneous pain and itch 319 
behaviour and hyperalgesia (Duan et al., 2014; Foster et al., 2015). While these studies and 320 
many others previously provide support for the important role of spinal circuitry, the actual 321 
circuits involved may be significantly more complex than originally proposed (Mendell, 322 
2014; Peirs and Seal, 2016) containing both excitatory and inhibitory interneurons. The 323 
precise identities of spinal neurons and circuits that transmit and gate pain related information 324 
remain largely unknown (Zeilhofer et al., 2012). 325 
One of the major barriers to identifying circuits that modulate noxious information is the 326 
difficulty in defining functional populations among the interneurons (Todd, 2017). As already 327 
stated there are two main types; inhibitory and excitatory interneurons. Inhibitory 328 
interneurons use γ-aminobutyric acid (GABA) or glycine as neurotransmitters although many 329 
co-express both (Todd, 2010) while excitatory interneurons use glutamate as a 330 
neurotransmitter. A number of classification schemes for superficial dorsal horn interneurons 331 
have been suggested and electrophysiological techniques can be used to identify subtypes by 332 
input or firing patterns (Yasaka et al., 2010). However, a morphological classification scheme 333 
(Grudt and Perl, 2002) has become a widely adopted classification. This describes four 334 
morphologically distinguishable interneurons: islet, central, radial and vertical cells. Some of 335 
these cells types have been associated with specific roles in nociceptive circuitry (Lu et al., 336 
2013; Lu and Perl, 2003) but this classification scheme leaves a substantial proportion of 337 
cells unclassified (Yasaka et al., 2007). An alternative approach to classification has been to 338 
use neurochemical markers such as neuropeptides, receptors, enzymes and calcium binding 339 
proteins that are expressed by discrete populations of interneurons. GABAergic interneurons 340 
have recently been divided into non-overlapping subpopulations defined by expression of 341 
galanin/dynorphin, neuropeptide Y, neuronal nitric oxide synthase and parvalbumin and these 342 
appear to be functionally as well as neurochemically distinct (Polgár et al., 2013; Duan et al., 343 
2014; Bourane et al., 2015; Petitjean et al., 2015). Excitatory interneurons have also recently 344 
been divided into distinct groups based on their expression of somatostatin, substance P, 345 
gastrin-releasing peptide and protein kinase C gamma (PKCδ) (Gutierrez-Mecinas et al., 346 
2016, 2017). 347 
Based on current knowledge, it is difficult to rationalise clinical or therapeutic decisions 348 
using our evolving knowledge of circuitry. However, manipulation of spinal circuits can 349 
powerfully influence nociceptive transmission in many ways. In particular circuits involving 350 
excitatory interneurons underlie the potential for touch information to be able to access 351 
nociceptive specific projection neurons via heterosynaptic facilitation, hence causing 352 
allodynia (Graham et al., 2007).  Recent studies have demonstrated the important roles of 353 
excitatory interneurons expressing somatostatin (Christensen et al., 2016; Duan et al., 2014), 354 
PKCδ (Lu et al., 2013) and vesicular glutamate transporter 3 (VGLUT3) (Peirs et al., 2015) 355 
in the generation of heightened pain states. Adequate inhibitory control of these pathways by 356 
the GABAergic or glycinergic interneuron population is important for prevention 357 
development of hyperalgesia and allodynia (Foster et al., 2015) . It is thought that a number 358 
of clinical chronic pain states may be due to disinhibition of spinal cord circuits. Quite why 359 
this may occur is not entirely clear but a promising mechanism may be due to downregulation 360 
of the neuronal potassium-chloride co-transporter (KCC2). This mechanism has been 361 
suggested to be driven by the microglial response in the dorsal horn seen after injury (Coull et 362 
al., 2005). While this mechanism is probably more important in chronic and neuropathic pain, 363 
it may still be important in acute inflammatory pain (McMahon and Malcangio, 2009). 364 
Interestingly, the spinal neuroimmune interactions underlying this sensitisation appear to 365 
differ between males and females in experimental studies, and this may underpin differences 366 
in clinical pain sensitivities between sexes (Mogil, 2012). 367 
Descending controls 368 
Descending control pathways from brainstem regions project to the dorsal horn of the spinal 369 
cord. They represent a mechanism through which the transmitted nociceptive signal may be 370 
facilitated - enhancing the pain experienced, or inhibited - reducing pain. They provide a top-371 
down mechanism whereby cognitive, emotional or autonomic factors can regulate pain 372 
processing at the dorsal horn (Bannister and Dickenson, 2017). One can see the potential 373 
advantages of antinociceptive mechanisms which can be engaged during 'fight or flight' 374 
situations for example. Inputs from many brain regions activate areas of the PAG and this in 375 
turn feeds into the RVM and locus coeruleus (LC). From here neurons project bilaterally to 376 
the dorsal horn where they release 5-hydroxytryptamine (5-HT) and noradrenaline (NA). 377 
Noradrenaline acts via α2-adrenoceptors resulting in antinociceptive effects. The situation 378 
with 5-HT is somewhat more complex as it can result in anti- or pro-nociceptive effects 379 
through action at either the 5-HT7 or 5-HT3 receptors respectively (Dogrul et al., 2009). 380 
Recent evidence points to RVM neurons releasing 5-HT having a predominantly facilitatory 381 
effect on nociceptive transmission (Cai et al., 2014). Notably, descending facilitation rather 382 
than inhibition predominates overall in young animals. This dominance alongside numerous 383 
other neurobiological changes may underlie the excitatory dominance that is a feature of pain 384 
in neonates and infants (Fitzgerald, 2015). 385 
One consequence of this descending pain modulation system is that one pain can inhibit 386 
another, e.g. an ear pinch may reduce the pain from a toe pinch. This phenomenon is termed 387 
diffuse noxious inhibitory controls (DNIC) and this can be easily evoked and quantified in 388 
animals and man, thus allowing measurement of the activity of the descending pathways 389 
(Bannister and Dickenson, 2017). Reduced DNIC is indicative of altered descending 390 
modulation which may be predictive of the actions of analgesic drugs and the degree of pain 391 
morbidity after injury (Yarnitsky, 2010). 392 
Representation of Pain in the Brain 393 
As outlined above, information from the spinal cord is projected to various centres in the 394 
brain and the resultant neuronal activity gives rise to the multidimensional experience that is 395 
pain. Functional imaging studies in humans and animals have increased our knowledge of the 396 
brain areas involved hugely (Borsook and Becerra, 2011; Guillot et al., 2015; Tracey and 397 
Mantyh, 2007). This combined set of brain regions is often referred to as the “pain matrix" 398 
and encompasses areas involved with sensory-discriminative, affective and cognitive aspects.  399 
However, the pain matrix is not entirely specific to pain in the way the visual cortex, for 400 
example, is to sight. Instead, none of the regions are unique to pain and many are involved in 401 
other aspects of perception and behaviour (Tracey and Johns, 2010). Recently the dorsal 402 
posterior insula, and its analogue in other animals, has been suggested as a fundamentally 403 
important site for tracking the intensity component of a noxious stimulus at a cerebral level 404 
(Segerdahl et al., 2015). However, while similar regions are implicated in cerebral pain 405 
processing and perception in both animals and humans (Thompson and Bushnell, 2012), it is 406 
currently unknown how the complex interplay between these areas determines what 407 
constitutes a painful experience across the phylogeny.  Cognitive and affective top-down 408 
regulation of pain via the ‘pain matrix’ also underlies the placebo and nocebo effects (Tracey, 409 
2010) which are reliant, at least in humans, on prior experience and expectation. The 410 
investigation of true placebo effects in animals is at a very early stage (Muñana et al., 2010). 411 
 412 
Conclusions 413 
Acute pain is common as a result of surgery, illness or injury and is undeniably unpleasant. 414 
Our knowledge of the circuits and cellular and molecular mechanisms underlying acute pain 415 
and plasticity is expanding rapidly. In parallel to this explosion of interest in nociceptive 416 
mechanisms, researchers are developing novel and highly specific pharmaceutical and 417 
genetic techniques to precisely manipulate biological systems. This knowledge should enable 418 
the development of new therapeutics and approaches to treating pain based on mechanistic 419 
principles with increased efficacy and fewer side effects; ultimately enabling veterinarians to 420 
treat pain and the resultant suffering in animals more effectively. 421 
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Figure Legends 703 
Fig 1.  704 
The dorsal horn of the spinal cord is divided into laminae. Different classes of cutaneous 705 
primary afferents have specific patterns of innervation of the dorsal horn. The figure 706 
demonstrates the stratification of the dorsal horn by somatosensory modality with those 707 
afferents carrying impulses resulting from noxious cutaneous stimuli primarily innervating 708 
laminae I and I, and those conveying touch signals projecting to the deeper laminae. (C-709 
LTMR stands for C-low threshold mechanoreceptor.) 710 
 711 
Fig 2.  712 
Projection neurons arise from the dorsal horn of the spinal cord. These innervate various 713 
higher centres responsible for aspects of the pain experience including the thalamus and the 714 
parabrachial nucleus. Neurons of the ventral medulla and midbrain periaqueductal gray are 715 
also engaged which may activate descending feedback systems. The simplified figure shows 716 
the sites of primary terminations from projection neurons. Initial activation of these areas 717 
forms the basis of a resultant coordinated activity in a multitude of brain regions which 718 
comprise the ‘pain matrix’. 719 
The figure shows a single projection neuron, in this case a spinothalamic tract (STT) neuron. 720 
Note - species differences exist in the white matter tracts for the projection of nociceptive 721 
information as detailed in the text. 722 
  723 
Tables 724 
Table 1 – The classification of primary afferents by fibre diameter and conduction velocity. 725 
Classification Diameter Myelin Conduction 
velocity 
Sensory Function 
Aβ Large (6–12 µm) Yes >35 m/s Touch 
Aδ Medium (1–5 µm) Thin 5-35 m/s ‘Fast’ pain 
C Small (0.2-1.5 μm) No <2.0 m/s ‘Slow’ pain 
 726 
